Effects of Budesonide & Budesonide/Formoterol on Smoking Asthmatic Subjects
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A reduced response to inhaled corticosteroids (ICS) has been reported in smoking compared to
non-smoking asthmatic patients. However, the comparative response to other currently
prescribed medications such as combination therapy of long-acting beta agonists and ICS
remain to be further evaluated.
No significant differences were found between our group of subjects in regard to changes in
asthma control pulmonary function and airway inflammation following budesonide or the
association of budesonide with formoterol for a period of 2 months. This should be further
explored in larger groups of subjects.
Phase:
Phase 3
Details
Lead Sponsor:
Laval University
Collaborator:
AstraZeneca
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination Formoterol Fumarate